Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan in Congenital Systemic Right Ventricle Heart Failure
NCT05117736Terminated
- Sponsor
- Montréal Heart Institute
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in heart failure (HF) comparing Sacubitril/Valsartan First with Placebo First (2 arms). Primary endpoints: Change of sub-maximal total exercise duration at 58 weeks and Change of NT-proBNP level at 58 weeks. Started Mar 2022; status: terminated.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05117736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117736.